Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQ-A3334 + anlotinib
- Development stage
- Discontinued
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TQ-A3334 + anlotinib is a combination therapy under investigation for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). TQ-A3334 is a small molecule agonist of Toll-like receptor 7 (TLR7), designed to stimulate innate immune responses and enhance anti-tumor immunity. Anlotinib, also known as catequentinib and marketed under the brand name Fukewei, is a multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor growth by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. The combination aims to leverage both immunomodulatory effects from TQ-A3334 and antiangiogenic/antitumor effects from anlotinib. Both drugs are developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., part of Sino Biopharm[1][2][3][7].
- Brand names
- Fukewei
- Other names
- Catequentinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TLR7 (Toll-like receptor 7)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on TQ-A3334 + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQ-A3334 + anlotinib.